We therefore developed a pipeline to identify PA cancer cells using four sources of information: (1) immunolabeling using a PA-specific marker; (2) enhanced BRAF fusion transcript detection; (3) clustering based on RNA-seq profiles; and (4) expressed glial tumor markers (Fig. 1a). The gene discussed is BRAF; the disease is cancer.